RENE — ReNeuron Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
- £1.93m
- -£2.80m
- £0.53m
R2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.049 | 6.07 | 0.257 | 0.403 | 0.53 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18.3 | 20.5 | 13.2 | 11.6 | 7.64 |
Operating Profit | -18.3 | -14.4 | -12.9 | -11.2 | -7.12 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -17.2 | -13.9 | -13.4 | -11.1 | -6.66 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.441 | -0.349 | -0.291 | -0.17 | -0.095 |